Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 28, 2016; 22(40): 9012-9021
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.9012
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.9012
Table 2 Other adverse events associated with thioguanine use
| Adverse event | Prevalence | Ref. |
| GI complaints | 1%-17% | [16,17,19,20,37,38] |
| Myelosuppression1 | 1%-15% | [17,20,36,38] |
| General malaise | 4%-22% | [17,38] |
| Allergic reaction | 1%-6% | [17,33] |
| Other AE (e.g., myalgia, alopecia) | 1%-38% | [16,17,19,20,33,36-38] |
- Citation: Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016; 22(40): 9012-9021
- URL: https://www.wjgnet.com/1007-9327/full/v22/i40/9012.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i40.9012